Anavex Life Sciences Corp (NASDAQ:AVXL) Reports Increase in Sellers; Strong Momentum for Short Players

May 17, 2018 - By Marie Mckinney

Anavex Life Sciences Corp. (NASDAQ:AVXL) Logo

The stock of Anavex Life Sciences Corp (NASDAQ:AVXL) registered an increase of 11.15% in short interest. AVXL’s total short interest was 5.88M shares in May as published by FINRA. Its up 11.15% from 5.29 million shares, reported previously. With 325,500 shares average volume, it will take short sellers 18 days to cover their AVXL’s short positions. The short interest to Anavex Life Sciences Corp’s float is 15.08%.

The stock increased 5.72% or $0.1396 during the last trading session, reaching $2.5796. About 120,420 shares traded. Anavex Life Sciences Corp. (NASDAQ:AVXL) has declined 55.59% since May 17, 2017 and is downtrending. It has underperformed by 67.14% the S&P500.

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of AlzheimerÂ’s disease, other central nervous system diseases, pain, and various cancers. The company has market cap of $115.21 million. The companyÂ’s lead drug candidates include ANAVEX 2-73, a Phase 2a clinical trial for the treatment of AlzheimerÂ’s disease; and preclinical stage to treat ParkinsonÂ’s disease. It currently has negative earnings. The Company’s preclinical drug candidates include ANAVEX 3-71, which uses ligands that activate sigma-1 and M1 muscarinic receptors to treat AlzheimerÂ’s disease; ANAVEX 1-41, a sigma-1 agonist that protects nerve cells from degeneration or death; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain.

More recent Anavex Life Sciences Corp. (NASDAQ:AVXL) news were published by: Globenewswire.com which released: “Anavex Life Sciences Reports Fiscal Second Quarter 2018 Financial Results” on May 10, 2018. Also Streetinsider.com published the news titled: “UPDATE: Maxim Assumes Anavex Life Sciences (AVXL) at Buy” on May 16, 2018. Seekingalpha.com‘s news article titled: “Anavex Life Sciences Corp’s (AVXL) CEO Christopher Missling on Q1 2018 Results – Earnings Call Transcript” with publication date: May 11, 2018 was also an interesting one.

Anavex Life Sciences Corp. (NASDAQ:AVXL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.